World's Best Scientists 2026 revealed!
Daniel F. Ortwine

Daniel F. Ortwine

D-Index & Metrics

Chemistry

D-Index
41
Citations
5782
World Ranking
17786
National Ranking
4340

Daniel F. Ortwine publication distribution in Chemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Chemistry in 2026. The highlighted bar marks where Daniel F. Ortwine sits on this spectrum.

61–80 publications: 66 scientists 81–100 publications: 302 scientists 101–120 publications: 623 scientists 121–140 publications: 918 scientists 141–160 publications: 1,218 scientists 161–180 publications: 1,350 scientists 181–200 publications: 1,344 scientists 201–220 publications: 1,281 scientists 221–240 publications: 1,216 scientists 241–260 publications: 1,100 scientists 261–280 publications: 979 scientists 281–300 publications: 939 scientists 301–320 publications: 764 scientists 321–340 publications: 643 scientists 341–360 publications: 628 scientists 361–380 publications: 522 scientists 381–400 publications: 459 scientists 401–420 publications: 397 scientists 421–440 publications: 327 scientists 441–460 publications: 270 scientists 461–480 publications: 265 scientists 481–500 publications: 252 scientists 501–520 publications: 201 scientists 521–540 publications: 185 scientists 541–560 publications: 148 scientists 561–580 publications: 148 scientists 581–600 publications: 132 scientists 601–620 publications: 114 scientists 621–640 publications: 104 scientists 641–660 publications: 91 scientists 661–680 publications: 92 scientists 681–700 publications: 73 scientists 701–720 publications: 57 scientists 721–740 publications: 54 scientists 741–760 publications: 67 scientists 761–780 publications: 45 scientists 781–800 publications: 46 scientists 801–820 publications: 39 scientists 821–840 publications: 32 scientists 841–860 publications: 36 scientists 861–880 publications: 29 scientists 881–900 publications: 26 scientists 901–920 publications: 24 scientists 921–940 publications: 14 scientists 941–960 publications: 23 scientists 961–980 publications: 28 scientists 981–1,000 publications: 15 scientists 1,001–1,020 publications: 29 scientists 1,021–1,040 publications: 12 scientists 1,041–1,060 publications: 19 scientists 1,061–1,080 publications: 12 scientists 1,081–1,100 publications: 6 scientists 1,101–1,120 publications: 8 scientists 1,121–1,140 publications: 12 scientists 1,141–1,160 publications: 5 scientists 1,161–1,180 publications: 6 scientists 1,181–1,200 publications: 14 scientists 1,201–1,220 publications: 7 scientists 1,221–1,240 publications: 2 scientists 1,241–1,260 publications: 6 scientists 1,261–1,280 publications: 4 scientists 1,281–1,294 publications: 6 scientists 1,295+ publications: 100 scientists
61 publications 1,295+

This scientist: 110 publications — 4th percentile

4% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,295 publications or more.

Daniel F. Ortwine D-index placement in Chemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Chemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Daniel F. Ortwine sits on this spectrum.

40–41 D-Index: 289 scientists 42–43 D-Index: 612 scientists 44–45 D-Index: 808 scientists 46–47 D-Index: 776 scientists 48–49 D-Index: 835 scientists 50–51 D-Index: 861 scientists 52–53 D-Index: 872 scientists 54–55 D-Index: 933 scientists 56–57 D-Index: 1,051 scientists 58–59 D-Index: 930 scientists 60–61 D-Index: 882 scientists 62–63 D-Index: 834 scientists 64–65 D-Index: 731 scientists 66–67 D-Index: 775 scientists 68–69 D-Index: 683 scientists 70–71 D-Index: 646 scientists 72–73 D-Index: 561 scientists 74–75 D-Index: 501 scientists 76–77 D-Index: 437 scientists 78–79 D-Index: 388 scientists 80–81 D-Index: 354 scientists 82–83 D-Index: 292 scientists 84–85 D-Index: 275 scientists 86–87 D-Index: 254 scientists 88–89 D-Index: 235 scientists 90–91 D-Index: 185 scientists 92–93 D-Index: 192 scientists 94–95 D-Index: 155 scientists 96–97 D-Index: 163 scientists 98–99 D-Index: 125 scientists 100–101 D-Index: 105 scientists 102–103 D-Index: 105 scientists 104–105 D-Index: 112 scientists 106–107 D-Index: 88 scientists 108–109 D-Index: 68 scientists 110–111 D-Index: 69 scientists 112–113 D-Index: 65 scientists 114–115 D-Index: 79 scientists 116–117 D-Index: 61 scientists 118–119 D-Index: 44 scientists 120–121 D-Index: 37 scientists 122–123 D-Index: 40 scientists 124–125 D-Index: 33 scientists 126–127 D-Index: 26 scientists 128–129 D-Index: 34 scientists 130–131 D-Index: 35 scientists 132–133 D-Index: 25 scientists 134–135 D-Index: 27 scientists 136–137 D-Index: 17 scientists 138–139 D-Index: 16 scientists 140–141 D-Index: 20 scientists 142–143 D-Index: 20 scientists 144–145 D-Index: 15 scientists 146–147 D-Index: 9 scientists 148–149 D-Index: 9 scientists 150–151 D-Index: 16 scientists 152–153 D-Index: 11 scientists 154–155 D-Index: 9 scientists 156–157 D-Index: 3 scientists 158 D-Index: 3 scientists 159+ D-Index: 98 scientists
40 D-Index 159+

This scientist: 41 D-Index — 2nd percentile

2% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 159 D-Index or more.

Overview

Daniel F. Ortwine is a researcher affiliated with Genentech in the United States, specializing in the fields of Medicine, Biochemistry, Genetics and Molecular Biology, and Materials Science. Their work spans several subfields, including Materials Chemistry, Molecular Biology, Genetics, Oncology, and Pulmonary and Respiratory Medicine.

The research topics addressed by Ortwine cover a range of biomedical and chemical areas such as:

  • Ion channel regulation and function
  • Estrogen and related hormone effects
  • HER2/EGFR in Cancer Research
  • Crystallization and Solubility Studies
  • X-ray Diffraction in Crystallography
  • Advanced Breast Cancer Therapies
  • Cardiac electrophysiology and arrhythmias

Ortwine has published multiple scholarly articles on these topics. Some of their recent publications include:

  • "GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer," 2021, Journal of Medicinal Chemistry
  • "Discovery of Acyl-sulfonamide Nav1.7 Inhibitors GDC-0276 and GDC-0310," 2021, Journal of Medicinal Chemistry
  • "Cryo-EM reveals an unprecedented binding site for NaV1.7 inhibitors enabling rational design of potent hybrid inhibitors," 2023, eLife
  • "Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer," 2021, Bioorganic & Medicinal Chemistry Letters
  • "BindingDB Entry 50008871: Discovery of a C-8 hydroxychromene as a potent degrader of estrogen receptor alpha with improved rat oral exposure over GDC-0927," 2021, PubMed

Their frequent coauthors include:

  • Jae H. Chang
  • Steven J. McKerrall
  • David H. Hackos
  • Antonio G. DiPasquale
  • Philippe Bergeron

Ortwine's work is published frequently in venues such as The Cambridge Structural Database, Journal of Medicinal Chemistry, Bioorganic & Medicinal Chemistry Letters, eLife, and ACS Medicinal Chemistry Letters, reflecting a focus on the intersection of chemistry and biomedical research.

Best Publications

  • Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability

    Benjamin E.L. Lauffer;Robert Mintzer;Rina Fong;Susmith Mukund

  • Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist.

    Shivani Ahuja;Susmith Mukund;Lunbin Deng;Kuldip Khakh

  • Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran-2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus.

    B D Roth;C J Blankley;A W Chucholowski;E Ferguson

  • Discovery and Characterization of a Novel Inhibitor of Matrix Metalloprotease-13 That Reduces Cartilage Damage in Vivo without Joint Fibroplasia Side Effects

    Adam R. Johnson;Alexander G. Pavlovsky;Daniel F. Ortwine;Faith Prior

  • Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.

    James J. Crawford;Adam R. Johnson;Dinah L. Misner;Lisa D. Belmont

  • Substituted 2-Benzothiazolamines as Sodium Flux Inhibitors: Quantitative Structure-Activity Relationships and Anticonvulsant Activity

    Sheryl J. Hays;Michael J. Rice;Daniel F. Ortwine;Graham Johnson

  • X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily.

    V. Dhanaraj;Q. Z. Ye;L. L. Johnson;D. J. Hupe

  • Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations

    Adam R. Johnson;Pawan Bir Kohli;Arna Katewa;Emily Gogol

  • 4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitution.

    Brian D Palmer;Andrew M Thompson;R John Booth;Ellen M Dobrusin

  • Structure−Activity Relationships and Pharmacokinetic Analysis for a Series of Potent, Systemically Available Biphenylsulfonamide Matrix Metalloproteinase Inhibitors

    Patrick M. O'brien;Daniel F. Ortwine;Alexander G. Pavlovsky;Joseph A. Picard

  • N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor.

    Alexander J. Bridges;Robert F. Bruns;Daniel F. Ortwine;Steven R. Priebe

  • GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.

    Jun Liang;Jason R Zbieg;Robert A Blake;Jae H Chang

  • Styrylpyrazoles, styrylisoxazoles, and styrylisothiazoles. Novel 5-lipoxygenase and cyclooxygenase inhibitors.

    Daniel L. Flynn;Thomas R. Belliotti;Amal M. Boctor;David T. Connor

  • Novel Series of Achiral, Low Molecular Weight, and Potent HIV-1 Protease Inhibitors

    J. V. N. Vara Prasad;Kimberly S. Para;Elizabeth A. Lunney;Daniel F. Ortwine

  • Benzothiopyranoindazoles, a new class of chromophore modified anthracenedione anticancer agents. Synthesis and activity against murine leukemias.

    Showalter Hd;Angelo Mm;Berman Em;Kanter Gd

  • Synthesis and structure-activity relationships of pyrazolo[4,3-d]pyrimidin-7-ones as adenosine receptor antagonists

    Harriet W. Hamilton;Daniel F. Ortwine;Donald F. Worth;James A. Bristol

  • X-RAY STRUCTURE OF GELATINASE A CATALYTIC DOMAIN COMPLEXED WITH A HYDROXAMATE INHIBITOR

    Venugopal Dhanaraj;Mark G. Williams;Qi Zhuang Ye;Franck Molina

  • A rationalization of the acidic pH dependence for stromelysin-1 (Matrix metalloproteinase-3) catalysis and inhibition.

    Linda L. Johnson;Alexander G. Pavlovsky;Adam R. Johnson;Jeffrey A. Janowicz

  • Quinazolinones and Pyrido[3,4-d]pyrimidin-4-ones as Orally Active and Specific Matrix Metalloproteinase-13 Inhibitors for the Treatment of Osteoarthritis

    Jie Jack Li;Joe Nahra;Adam R. Johnson;Amy Bunker

  • X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity.

    Alexander G. Pavlovsky;Mark G. Williams;Qi Zhuang Ye;Daniel F. Ortwine

  • Inhibitors of cholesterol biosynthesis. 1. trans-6-(2-pyrrol-1-ylethyl)-4-hydroxypyran-2-ones, a novel series of HMG-CoA reductase inhibitors. 1. Effects of structural modifications at the 2- and 5-positions of the pyrrole nucleus.

    Bruce D. Roth;D. F. Ortwine;M. L. Hoefle;C. D. Stratton

Frequent Co-Authors

Frederick Cohen
Frederick Cohen Nurix Therapeutics
Tom L. Blundell
Tom L. Blundell University of Cambridge
William A. Denny
William A. Denny University of Auckland

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in expanding their expertise beyond traditional chemistry, there are several related fields that offer strong career opportunities. One such area is forensic science, which combines chemical knowledge with criminal investigations. Many students explore options at online colleges for forensic science that provide flexible learning paths tailored to this interdisciplinary study.

For those looking to integrate psychology with legal and criminal justice systems, pursuing an online forensic psychology masters can be a valuable option. This degree opens doors to careers in behavioral analysis and criminal profiling, complementing a background in chemistry or forensic science.

Understanding the broad forensic career paths available helps students align their education with professional goals. From crime lab analyst to legal consultant, these paths benefit from interdisciplinary knowledge and practical skills acquired through specialized online programs.

Cost is a key consideration when selecting an online degree. Resources focused on how much is a criminal justice degree provide valuable insights into tuition, fees, and financial aid. Evaluating these costs upfront ensures students make informed decisions about their education investment.

Best Scientists Citing Daniel F. Ortwine

Trending Scientists

Recently Published Articles